The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie A Razavi, Imam A Waked, Christoph M Sarrazin, Robert P Myers, Ramazan Idilman, Filipe Calinas, W Vogel, Maria Cassia Jacintho Mendes-Correa, Christophe Hezode, P Lazaro, Ulus Salih Akarca, Soo Aleman, Ismail Balik, T Berg, Florian K Bihl, M Bilodeau, A J Blasco, Carlos Eduardo Brandao-Mello, Philip Bruggmann, Maria Asuncion ButiJ L Calleja, Hugo Cheinquer, P B Christensen, M Clausen, H S M Coelho, Matthew E Cramp, Gregory J Dore, Wahid H Doss, Ann Sofi Duberg, M H El-Sayed, Gul Ergor, Gamal Esmat, K Falconer, J Felix, M L G Ferraz, P R Ferreira, Sona Frankova, Javier Garcia-Samaniego, J Gerstoft, Jose A Giria, Fernando Lopes Goncales, Erin E Gower, Michael Gschwantler, M Guimaraes Pessoa, S J Hindman, H Hofer, P Husa, M Kaberg, Kelly Kaita, Achim Kautz, Sabahattin Kaymakoglu, Mel Krajden, H Krarup, Wim J Laleman, D Lavanchy, R T Marinho, P Marotta, Stefan Mauss, Christophe A Moreno, K Murphy, Francesco Negro, V Nemecek, Necati Ormeci, Anne Lindebo Holm Ovrehus, J Parkes, Ken Pasini, Kevork Minas Peltekian, Alnoor S Ramji, N Reis, Stuart Keith Roberts, William M C Rosenberg, Francoise Roudot-Thoraval, Stephen D Ryder, Rui Sarmento-Castro, David Semela, M Sherman, Gamal Elsayed Shiha, William Sievert, J Sperl, Peter Starkel, R E Stauber, Alexander James V Thompson, P Urbanek, P Van Damme, I Van Thiel, H Van Vlierberghe, Dominique M Vandijck, Heiner Wedemeyer, N Weis, J Wiegand, Ayman Yosry, Amany Zekry, Markus Cornberg, B Mullhaupt, Chris Estes

Research output: Contribution to journalArticleResearchpeer-review

283 Citations (Scopus)

Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today s treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
Original languageEnglish
Pages (from-to)34 - 59
Number of pages26
JournalJournal of Viral Hepatitis
Volume21
Issue numberSupplement S1
DOIs
Publication statusPublished - 2014

Cite this